On October 23, 2009 the U.S. Food & Drug Administration (FDA) issued an urgent warning to patients and physicians regarding Rituxan. The FDA and the drugs manufacturer have learned of a third case of Rituxan induced progressive multifocal leukoencephalopathy (PML).
Provided below are links to the FDA and manufacturers website(s):
- FDA: Rituxan (rituximab) – PML
- Genentech, Inc. and Biogen Idec, Inc: IMPORTANT DRUG WARNING Regarding RITUXAN® (Rituximab)